title: Ten years experience with belatacept-based immunosuppression after kidney transplantation.
abstract: BACKGROUND
  Belatacept was approved for prevention of acute rejection in adult kidney transplantation in 2011 based on two randomized, controlled, multicenter phase 3 studies. Long-term experience over 10 years with belatacept-based immunosuppression after kidney transplantation has not been reported before.
  
  
  METHODS
  Analyzed were 20 patients who had been included into a randomized multicenter phase 2 study by our institution between March 2001 and November 2002. For 10-year follow-up, three different groups could be analyzed: 1) patients with primary calcineurin inhibitor-based (CNI-based) immunosuppression (n = 5), 2) patients with early switch from a belatacept-based to a CNI-based regimen within the first 14 months (n = 8) and 3) patients with completely CNI-free belatacept immunosuppression (n = 7).
  
  
  RESULTS
  Fifteen patients received primary belatacept-based immunosuppression and five patients primary cyclosporine A (CyA). Five patients are still on belatacept. Kidney function measured by serum creatinine levels worsened in the CNI group and the belatacept to CNI switch group during long-term follow-up whereas all patients receiving belatacept throughout follow-up showed stable creatinine values. Acute rejections occurred predominantly in the first 12 months after transplantation and were responsible for four of seven switches from belatacept- to CNI-based immunosuppression within the first 14 months. Five of the 20 patients died.
  
  
  CONCLUSIONS
  Belatacept is effective and safe in renal transplant patients and was not associated with graft loss due to chronic allograft nephropathy. Belatacept was well tolerated in all patients and caused less nephrotoxic side effects and was well accepted in most patients.
authors.affiliation: Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule, Hannover, Germany.
authors.forename: Gerrit
authors.initials: G
authors.lastname: Grannas
authors.affiliation: Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule, Hannover, Germany.
authors.forename: Harald
authors.initials: H
authors.lastname: Schrem
authors.affiliation: Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule, Hannover, Germany.
authors.forename: Juergen
authors.initials: J
authors.lastname: Klempnauer
authors.affiliation: Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule, Hannover, Germany.
authors.forename: Frank
authors.initials: F
authors.lastname: Lehner
keywords: Acute rejection; Belatacept; Chronic allograft Nephropathy; Immunmodulation; Immunosuppression; Kidney transplantation; Long-term kidney function; Nephrotoxicity